Evolution of multiple cell clones over a 29-year period of a CLL patient

Zhikun Zhao, Lynn Goldin, Shiping Liu, Liang Wu, Weiyin Zhou, Hong Lou, Qichao Yu, Shirley X. Tsang, Miaomiao Jiang, Fuqiang Li, MaryLou McMaster, Yang Li, Xinxin Lin, Zhifeng Wang, Liqin Xu, Gerald Marti, Guibo Li, Kui Wu, Meredith Yeager, Huanming Yang, Xun Xu, Stephen J. Chanock, Bo Li (), Yong Hou (), Neil Caporaso () and Michael Dean ()
Additional contact information
Zhikun Zhao: BGI-Shenzhen
Lynn Goldin: National Cancer Institute (NCI), National Institutes of Health (NIH)
Shiping Liu: BGI-Shenzhen
Liang Wu: BGI-Shenzhen
Weiyin Zhou: Cancer Genomics Research Laboratory, National Cancer Institute, Leidos Biomedical Research Inc.
Hong Lou: Cancer Genomics Research Laboratory, National Cancer Institute, Leidos Biomedical Research Inc.
Qichao Yu: BGI-Shenzhen
Shirley X. Tsang: Biomatrix
Miaomiao Jiang: BGI-Shenzhen
Fuqiang Li: BGI-Shenzhen
MaryLou McMaster: National Cancer Institute (NCI), National Institutes of Health (NIH)
Yang Li: BGI-Shenzhen
Xinxin Lin: BGI-Shenzhen
Zhifeng Wang: BGI-Shenzhen
Liqin Xu: BGI-Shenzhen
Gerald Marti: Center for Devices and Radiological Health, Food and Drug Administration
Guibo Li: BGI-Shenzhen
Kui Wu: BGI-Shenzhen
Meredith Yeager: Cancer Genomics Research Laboratory, National Cancer Institute, Leidos Biomedical Research Inc.
Huanming Yang: BGI-Shenzhen
Xun Xu: BGI-Shenzhen
Stephen J. Chanock: National Cancer Institute (NCI), National Institutes of Health (NIH)
Bo Li: BGI-Shenzhen
Yong Hou: BGI-Shenzhen
Neil Caporaso: National Cancer Institute (NCI), National Institutes of Health (NIH)
Michael Dean: BGI-Shenzhen

Nature Communications, 2016, vol. 7, issue 1, 1-10

Abstract: Abstract Chronic lymphocytic leukaemia (CLL) is a frequent B-cell malignancy, characterized by recurrent somatic chromosome alterations and a low level of point mutations. Here we present single-nucleotide polymorphism microarray analyses of a single CLL patient over 29 years of observation and treatment, and transcriptome and whole-genome sequencing at selected time points. We identify chromosome alterations 13q14−, 6q− and 12q+ in early cell clones, elimination of clonal populations following therapy, and subsequent appearance of a clone containing trisomy 12 and chromosome 10 copy-neutral loss of heterogeneity that marks a major population dominant at death. Serial single-cell RNA sequencing reveals an expression pattern with high FOS, JUN and KLF4 at disease acceleration, which resolves following therapy, but reoccurs following relapse and death. Transcriptome evolution indicates complex changes in expression occur over time. In conclusion, CLL can evolve gradually during indolent phases, and undergo rapid changes following therapy.

Date: 2016
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms13765 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms13765

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms13765

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().